Trial
NCT02978222
Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Marker Therapeutics, Inc.
Collaborators
—
Condition
Platinum Sensitive Ovarian Cancer
Intervention
FRα peptide plus Adjuvant (GM-CSF)
Why stopped
Futility analysis did not support continuation of the trial
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-12-15